REVOIMMUNE THERAPEUTICS
RevoImmune Therapeutics focuses on the research and development and application of viral vectors and tumor immunotherapy technologies.
REVOIMMUNE THERAPEUTICS
Industry:
Health Care Medical Therapeutics
Address:
Shanghai, Shanghai, China
Country:
China
Status:
Active
More informations about "RevoImmune Therapeutics"
T-Cell Technology & Development | RevImmune | United States
RevImmune specialises in T-Cell Technology & Development. Our product IL-7 provides a global T-cell support for Immunotherapies.See details»
RevoImmune Therapeutics - Crunchbase Company Profile & Funding
RevoImmune Therapeutics focuses on the research and development and application of viral vectors and tumor immunotherapy technologies.See details»
About Us | RevImmune
Headquartered in Bethesda, Maryland, USA with a fully operational subsidiary in Paris, FranceSee details»
Cancer Research Institute and RevImmune Announce …
Mar 30, 2021 · RevImmune is a privately held biotech company based in France, the U.S. and the U.K. RevImmune is in multiple Phase II trials with CYT107 for treatment of sepsis, certain infectious diseases, and certain cancers.See details»
OUR PIPELINE - RevImmune
RevImmune’s platform technology is focused on IL-7, which plays a key role in T cell development, expansion, proliferation and mobilization. Importantly, IL-7 plays such a central …See details»
RevoImmune Therapeutics - Tech Stack, Apps, Patents & Trademarks
RevoImmune Therapeutics focuses on the research and development and application of viral vectors and tumor immunotherapy technologies.See details»
RevImmune Announces Phase II Trial of the T-Cell Growth Factor …
BETHESDA, Md., June 29, 2020 /PRNewswire/ -- RevImmune, a privately held biotechnology company developing CYT107 immune therapy for infectious diseases and cancer, announced …See details»
RevoImmune Therapeutics - Products, Competitors, Financials, …
RevoImmune Therapeutics's latest funding round is Unattributed VC. Who are the investors of RevoImmune Therapeutics? Investors of RevoImmune Therapeutics include Lead Wealth …See details»
RevoImmune Therapeutics - Crunchbase
RevoImmune Therapeutics focuses on the research and development and application of viral vectors and tumor immunotherapy technologies.See details»
Revimmune Company Profile 2024: Valuation, Investors
Developer of therapies for autoimmune diseases.See details»
How the science works - RevImmune
Recognition of cancer cells by T cells. 1. Release of cancer antigens. 7. Killing of cancer cells. IL-7 acting at many levels of T-Cell production. IL-7 Key Effects to support Immune recovery.See details»
Accentia Biopharmaceuticals Announces that Revimmune …
May 4, 2011 · Revimmune therapy is believed to act by completely eliminating mature lymphocytes throughout the body while selectively sparing immune stem cells in the bone …See details»
Shanghai Revolmmune Therapeutics Biotechnology Ltd
Shanghai Revolmmune Therapeutics Biotechnology Ltd. (Revolmmune) - BioCentury Company Profiles for the biopharma industrySee details»
Home - EvolveImmune
EvolveImmune Therapeutics is pioneering a new class of precision cancer medicines to deliver superior patient outcomes compared to current anti-cancer therapies. We have validated new …See details»
RevImmune advances new immunotherapy in COVID-19 - PR …
BETHESDA, Md., Nov. 2, 2020 /PRNewswire/ -- RevImmune, a privately held biotech company based in Paris, France and Bethesda, MD, developing CYT107 (recombinant human …See details»
RevoImmune Therapeutics Stock Price, Funding, Valuation, …
Sep 4, 2020 · See RevoImmune Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on RevoImmune Therapeutics's post-money valuation …See details»
Clinical Development - RevImmune
Hematopoietic Stem Cell Transplant: first proof in hematology. Early Combination with Anti-PD1. The natural human sequence. Clinical Development Infectious Diseases; Sepsis, Non …See details»
A sensitive mitochondrial thermometry 2.0 and the availability of ...
Aug 24, 2022 · We previously developed a quantifiable mitochondrial thermometry 1.0 based on rhodamine B methyl ester (RhB-ME) and rhodamine 800 (Rh800), and the theory for …See details»
Press & Publications - RevImmune
Mar 8, 2018 · Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Daix T, Mathonnet A, …See details»
Shanghai Revolmmune Therapeutics Biotechnology Limited …
Jul 13, 2020 · Shanghai Revolmmune Therapeutics Biotechnology Limited announced that it has entered into an equity investment agreement with a new investor, China Grand …See details»